We showed recently that human activated lymphocytes express the elastin-laminin receptor. In this study, we were interested in the kinetics of the induction of this receptor on human activated lymphocytes in vitro and in the quantification of its expression on different human lymphocyte subsets. It appears that the expression of the elastin-laminin receptor is a general property of most activated human lymphocytes but strongly dependent on the lymphocyte subsets. It appeared that the helper (CD4+) and memory (CD45RO+) lymphocytes exhibited the strongest increase of elastin-laminin receptor expression when cultured for 72 h in the presence of 2 μg/ml elastin peptides (2.7 × 10––8 M) as compared to control cells. Activation of this receptor by elastin peptides triggers the stimulation of biosynthesis and release of a PMN-like elastase. Activated T lymphocytes (mostly helper and memory T cells) are present from early stages of the atherosclerotic process and this release could contribute to the progression of the lesion by engaging a vicious circle with more elastin peptides released attracting more mono-nuclear cells and increasing their elastase production.

Keywords:
Lymphocytes human, Elastin-laminin receptor, Elastin peptides
This content is only available via PDF.
© 1997 S. Karger AG, Basel
1997
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.